Biologic therapies in type 1 diabetes: how far are they from us?

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2013-11, Vol.126 (21), p.4003-4005
Main Authors: Deng, Chao, Xiang, Yu-Fei, Zhou, Zhi-Guang
Format: Article
Language:English
Subjects:
Abatacept
Antibodies, Monoclonal, Humanized - therapeutic use
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Biological Therapy - methods
Diabetes Mellitus, Type 1 - drug therapy
Humans
Immunoconjugates - therapeutic use
Rituximab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c411t-be65fe7a365183085e1820f0e24cbbc03beaa8752bb928a9ef0c7951f9ce58b3
cites cdi_FETCH-LOGICAL-c411t-be65fe7a365183085e1820f0e24cbbc03beaa8752bb928a9ef0c7951f9ce58b3
container_end_page 4005
container_issue 21
container_start_page 4003
container_title Chinese medical journal
container_volume 126
creator Deng, Chao
Xiang, Yu-Fei
Zhou, Zhi-Guang
description
doi_str_mv 10.3760/cma.j.issn.0366-6999.20132375
format article
fullrecord <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_zhcmj201321001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><wanfj_id>zhcmj201321001</wanfj_id><sourcerecordid>zhcmj201321001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-be65fe7a365183085e1820f0e24cbbc03beaa8752bb928a9ef0c7951f9ce58b3</originalsourceid><addsrcrecordid>eNo9kEtLxDAQx3NQXF39CpKL4mVrHk3aCOILX7DgZe8hyU7clr5MWmT99LauepmB4fefYX4InVGS8EySS1ebpEyKGJuEcCkXUimVMEI545nYQ4f_wxk6irEkhAmRyQM0YyljSsr0EN3eF23VvhcO9xsIpisg4qLB_bYDTPG6MBZ6iFd4035ibwI2ASZyi31oazzEm2O0700V4eS3z9Hq6XH18LJYvj2_PtwtFy6ltF9YkMJDZrgUNOckF0BzRjwBljprHeEWjMkzwaxVLDcKPHGZEtQrByK3fI7Od2s_TeNN867LdgjNeFB_bVxd_jxNyVjn6GIHdqH9GCD2ui6ig6oyDbRD1DQViqZKEDGi1zvUhTbGAF53oahN2GpK9CRYj4J1qSfBenKpJ5f6T_CYP_09Ndga1v_pP7v8GxjAers</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1459149505</pqid></control><display><type>article</type><title>Biologic therapies in type 1 diabetes: how far are they from us?</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><creator>Deng, Chao ; Xiang, Yu-Fei ; Zhou, Zhi-Guang</creator><creatorcontrib>Deng, Chao ; Xiang, Yu-Fei ; Zhou, Zhi-Guang</creatorcontrib><identifier>ISSN: 0366-6999</identifier><identifier>DOI: 10.3760/cma.j.issn.0366-6999.20132375</identifier><identifier>PMID: 24229664</identifier><language>eng</language><publisher>China: Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011, China</publisher><subject>Abatacept ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Biological Therapy - methods ; Diabetes Mellitus, Type 1 - drug therapy ; Humans ; Immunoconjugates - therapeutic use ; Rituximab</subject><ispartof>Chinese medical journal, 2013-11, Vol.126 (21), p.4003-4005</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-be65fe7a365183085e1820f0e24cbbc03beaa8752bb928a9ef0c7951f9ce58b3</citedby><cites>FETCH-LOGICAL-c411t-be65fe7a365183085e1820f0e24cbbc03beaa8752bb928a9ef0c7951f9ce58b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.wanfangdata.com.cn/images/PeriodicalImages/zhcmj/zhcmj.jpg</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24229664$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deng, Chao</creatorcontrib><creatorcontrib>Xiang, Yu-Fei</creatorcontrib><creatorcontrib>Zhou, Zhi-Guang</creatorcontrib><title>Biologic therapies in type 1 diabetes: how far are they from us?</title><title>Chinese medical journal</title><addtitle>Chin Med J (Engl)</addtitle><subject>Abatacept</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>Biological Therapy - methods</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Humans</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Rituximab</subject><issn>0366-6999</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNo9kEtLxDAQx3NQXF39CpKL4mVrHk3aCOILX7DgZe8hyU7clr5MWmT99LauepmB4fefYX4InVGS8EySS1ebpEyKGJuEcCkXUimVMEI545nYQ4f_wxk6irEkhAmRyQM0YyljSsr0EN3eF23VvhcO9xsIpisg4qLB_bYDTPG6MBZ6iFd4035ibwI2ASZyi31oazzEm2O0700V4eS3z9Hq6XH18LJYvj2_PtwtFy6ltF9YkMJDZrgUNOckF0BzRjwBljprHeEWjMkzwaxVLDcKPHGZEtQrByK3fI7Od2s_TeNN867LdgjNeFB_bVxd_jxNyVjn6GIHdqH9GCD2ui6ig6oyDbRD1DQViqZKEDGi1zvUhTbGAF53oahN2GpK9CRYj4J1qSfBenKpJ5f6T_CYP_09Ndga1v_pP7v8GxjAers</recordid><startdate>20131105</startdate><enddate>20131105</enddate><creator>Deng, Chao</creator><creator>Xiang, Yu-Fei</creator><creator>Zhou, Zhi-Guang</creator><general>Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011, China</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>20131105</creationdate><title>Biologic therapies in type 1 diabetes: how far are they from us?</title><author>Deng, Chao ; Xiang, Yu-Fei ; Zhou, Zhi-Guang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-be65fe7a365183085e1820f0e24cbbc03beaa8752bb928a9ef0c7951f9ce58b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Abatacept</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>Biological Therapy - methods</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Humans</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deng, Chao</creatorcontrib><creatorcontrib>Xiang, Yu-Fei</creatorcontrib><creatorcontrib>Zhou, Zhi-Guang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deng, Chao</au><au>Xiang, Yu-Fei</au><au>Zhou, Zhi-Guang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biologic therapies in type 1 diabetes: how far are they from us?</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chin Med J (Engl)</addtitle><date>2013-11-05</date><risdate>2013</risdate><volume>126</volume><issue>21</issue><spage>4003</spage><epage>4005</epage><pages>4003-4005</pages><issn>0366-6999</issn><cop>China</cop><pub>Diabetes Center, Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan 410011, China</pub><pmid>24229664</pmid><doi>10.3760/cma.j.issn.0366-6999.20132375</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0366-6999
ispartof Chinese medical journal, 2013-11, Vol.126 (21), p.4003-4005
issn 0366-6999
language eng
recordid cdi_wanfang_journals_zhcmj201321001
source HEAL-Link subscriptions: Lippincott Williams & Wilkins
subjects Abatacept
Antibodies, Monoclonal, Humanized - therapeutic use
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Biological Therapy - methods
Diabetes Mellitus, Type 1 - drug therapy
Humans
Immunoconjugates - therapeutic use
Rituximab
title Biologic therapies in type 1 diabetes: how far are they from us?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A52%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biologic%20therapies%20in%20type%201%20diabetes:%20how%20far%20are%20they%20from%20us?&rft.jtitle=Chinese%20medical%20journal&rft.au=Deng,%20Chao&rft.date=2013-11-05&rft.volume=126&rft.issue=21&rft.spage=4003&rft.epage=4005&rft.pages=4003-4005&rft.issn=0366-6999&rft_id=info:doi/10.3760/cma.j.issn.0366-6999.20132375&rft_dat=%3Cwanfang_jour_proqu%3Ezhcmj201321001%3C/wanfang_jour_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c411t-be65fe7a365183085e1820f0e24cbbc03beaa8752bb928a9ef0c7951f9ce58b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1459149505&rft_id=info:pmid/24229664&rft_wanfj_id=zhcmj201321001&rfr_iscdi=true